Longitudinal Cohort Study Demonstrates Notable Rate of > 3% BMD Loss Over 2 Yrs Among MSM Receiving TDF-Based PrEP

IDWeek 2019; October 2-6, 2019; Washington, DC
21st International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; November 5-6, 2019; Basel, Switzerland
17th European AIDS Conference; November 6-9, 2019; Basel, Switzerland
This small prospective study found that sizeable proportions of MSM (24% to 35%) experienced more than 3% BMD loss in the femur, spine, and hip after 2 years of TDF-based PrEP.
Format: Microsoft PowerPoint (.ppt)
File Size: 163 KB
Released: November 19, 2019

Acknowledgements

Provided by USF Health

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Understand medical, social, and emotional challenges faced by older PWH, from Clinical Care Options (CCO)

Jonathan Appelbaum, MD, FACP, AAHIVS
Program Director
Melanie Reese
Program Director
Lydia Mungherera, MBChB Cristina Mussini, MD Dorothy Onyango Marc Thompson
Released: August 9, 2022

Clinical Care Options (CCO) presents patient advocate and patient discussing the importance of overcoming local barriers to HIV care for women

person default Angelina Namiba Released: August 5, 2022

Safety and efficacy of broadly neutralizing antibody VRC01 with early ART in infants with HIV, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 5, 2022

HIV self-testing and 6-month PrEP dispensing simplified PrEP delivery with no reduction in HIV testing or PrEP adherence, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 5, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings